Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
387 studies found for:    biogen | biogen
Show Display Options
RSS Create an RSS feed from your search for:
biogen | biogen
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Biogen Multiple Sclerosis Pregnancy Exposure Registry
Conditions: Multiple Sclerosis;   Exposure During Pregnancy
Interventions: Drug: dimethyl fumarate;   Drug: Peginterferon beta-1a;   Drug: Dalclizumab High Yield Process
2 Completed Open-Label Safety Extension Study of Avonex
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1a (Avonex)
3 Terminated 104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants
Condition: Rheumatoid Arthritis
Intervention: Biological: Baminercept alfa (BG9924)
4 Terminated BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)
Condition: Rheumatoid Arthritis
Intervention: Drug: BG9924
5 Completed A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers
Condition: Healthy
Interventions: Drug: dimethyl fumarate - Reference form;   Drug: dimethyl fumarate - Test form
6 Completed ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
Condition: Multiple Sclerosis
7 Completed Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
Condition: Multiple Sclerosis
Intervention: Drug: low immunogenic interferon-beta-1a
8 Completed Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: Interferon-beta-1a;   Drug: methylprednisolone
9 Recruiting An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice
Condition: Multiple Sclerosis
Intervention: Drug: Fampridine
10 Completed Open-Label Natalizumab Safety Extension Study
Condition: Multiple Sclerosis
Intervention: Drug: Natalizumab
11 Completed Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Natalizumab;   Drug: Placebo
12 Completed BG9928 in Subjects With Hepatic Impairment
Condition: Hepatic Impairment
Intervention: Drug: BG9928
13 Completed Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe
Condition: Multiple Sclerosis
Interventions: Drug: Interferon beta-1a;   Device: Single-use autoinjector
14 Completed Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1a (Avonex)
15 Completed A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers
Condition: Multiple Sclerosis
Interventions: Drug: Serum containing Avonex;   Drug: Serum Free Avonex
16 Completed Immunogenicity and Safety Study of Serum-Free Avonex
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1a
17 Completed Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1a
18 Terminated How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: Interferon beta-1a
19 Completed GER-009-06-AVX Early Therapy in Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
20 Completed Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors
Conditions: Tumors;   Lymphoma
Intervention: Drug: CNF2024

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years